Femasys announces historic milestone with european approval of fembloc®, the first non-surgical permanent birth control

Atlanta, june 25, 2025 (globe newswire) -- femasys inc., (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces conformitÉ europÉene (ce) mark certification under european union medical device regulation (eu mdr 2017/745) of the class iii fembloc blended polymer component, marking the first regulatory approval in the world for the fembloc® system for non-surgical female permanent birth control. after european medicines agency (ema) review, the notified body has granted ce mark certification.
FEMY Ratings Summary
FEMY Quant Ranking